US Food and Drug Administration approval of the Gardasil 9 HPV vaccine has been expanded to include people ages 27 through 45.
Women with high-risk human papillomavirus are at higher risk for developing cardiovascular disease than women without high-risk HPV
From 2008 to 2015, both cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ rates and cervical cancer screening declined in women age 18 to 24 years.
Proportion of teens up to date with HPV vaccines also increasing; reached 48.6 percent in 2017.
The prevalence of oral high-risk HPV infection in adult men and women is low in England.
Catch-up quadrivalent HPV vaccination with 3 doses was effective against the risk for CIN2+ and CIN3+ in girls and women age 14-20 at time of first vaccine dose but not for women age 21 and older at first dose.
Implementation of state legislation relating to HPV vaccination is not associated with changes in adolescent sexual behaviors.
In this Canadian, randomized controlled trial, the use of primary HPV testing compared with cytology resulted in a significantly lower likelihood of CIN3+ at 48 months.
Following quadrivalent human papillomavirus (HPV4) vaccination, girls age 12 to 17 years do not have increased risk of autoimmune disorders.
The 9-valent HPV vaccine could be a therapeutic option for patients with cutaneous squamous cell carcinoma when surgical management is not an option.
In women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing results in a significantly lower likelihood of cervical intraepithelial neoplasia grade 3 or higher at 48 months.
Specifically, the types the vaccine protects against are HPV 16, 18, 31, 33, 45, 52, 58 (which cause ~90% of cervical cancer cases worldwide), and types 6 and 11 which case genital warts.
Investigators examined parental hesitancy when discussing human papillomavirus vaccination with providers.
Providers engaging parents hesitant about human papillomavirus vaccination and addressing their concerns can lead to same-day vaccinations.
High-certainty evidence that HPV vaccination may provide protection in adolescent girls and young women aged 15 to 26 years.
The authors concluded, "There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26," while also indicated that future studies should have long-term follow-up.
Investigators sought to determine the link between HPV vaccination and the risk of developing multiple sclerosis.
Based on these data and the potential change in follow-up care, the HPV mRNA assay should not be used for a primary screening tool for cervical cancer.
The HR-HPV types covered by the nonavalent HPV vaccine had similar clearance rates to HR-HPV types not included, and women infected with multiple anogenital HR-HPV types had lower rates of clearance than women infected with only 1 type.
Adolescent consent may help minimize delays in vaccination and reduce the overall incidence of cervical, oropharyngeal, and anal cancers.
A bundled intervention including communication skills training and performance feedback may improve human papillomavirus vaccination.
For adolescents, a health care professional HPV vaccine communication intervention is associated with improved HPV vaccine series initiation and completion.
Study confirms HPV16 as an important determinant of high-grade lesions and supports its place as a priority for anal cancer prevention.
Deintensification of treatment from chemoradiotherapy to one modality may compromise safety in patients with human papillomavirus (HPV)+ stage 1 or 2 oropharyngeal cancer.
The limitations of herd protection for vaccine-type HPV was examined in a recent study.
Study was the first to examine the geographical variation of seminal HPV prevalence, showing a relatively high prevalence in fertility clinic attendees when compared to the general population.
For patients with HPV-associated cancers, there are large disparities in survival based on sex, race, and age.
Successive negative HPV and cytology co-testing is linked decrease risks of cervical cancer.
Findings inform further refinement of cervical cancer screening algorithms for vaccinated populations.
Incidence of juvenile-onset respiratory papillomatosis declined with the introduction of a HPV vaccination program.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- The Misuse of Antibiotics in Acute Pancreatitis Appears Widespread
- ART Reduces Neurocognitive Impairment in Patients Living With HIV
- Polio-Like Condition in Children on Rise in the United States
- Pneumococcal H Influenzae Protein D Conjugate Vaccine Effective in Children
- Mental Health Problems in Adolescents With HIV: Overview & Expert Interview
- Updated HCV Treatment Guidelines for 2018 Published by AASLD-IDSA
- Vitamin C Treatment May Be Beneficial for Sepsis, But Duration and Dose Unclear
- Piperacillin-Tazobactam vs Meropenem for Resistant Bloodstream Infections
- Eravacycline Now Available for Treating Complicated Intra-Abdominal Infections
- Risk Factors for Multidrug-Resistant Pathogens in Pneumonia